CONKLING WILLIAM 4

What Happened William Conkling, Chief Commercial Officer of Protara Therapeutics (TARA), was granted a total of 184,000 restricted stock units (RSUs) on January 16, 2026. The filing reports two award entries: 26,000 RSUs and 158,000 RSUs, each reported at $0.00 (grant). These are awards/derivative RSU grants (not open-market purchases or sales) and represent contingent rights to receive common stock if and when the RSUs vest.

Key Details

• Transaction date: January 16, 2026; reported filing date: January 21, 2026.
• Grants: 26,000 RSUs (reported as acquired at $0.00) and 158,000 RSUs (reported as derivative/awarded at $0.00) = 184,000 RSUs total.
• Shares owned after transaction: not specified in the Form 4.
• Vesting/footnotes:
  • One grant vests in equal one-third installments on the first, second and third anniversaries of January 16, 2026, subject to continued service.
  • The other grant vests 25% on the one-year anniversary (Jan 16, 2027) and then 1/48th monthly thereafter over the next three years, subject to continued service.
• Filing timeliness: The Form 4 was filed five calendar days after the transaction (Jan 21 for Jan 16); this appears to exceed the standard two-business-day filing deadline for insiders.

Context These entries are compensation awards (RSUs) rather than purchases or exercises. RSUs are contingent rights to receive shares upon vesting and typically reflect equity-based pay; they do not by themselves indicate a buy/sell market signal until shares actually vest or are sold. One of the grants was reported as a derivative-type award—meaning the award represents a future right to receive shares rather than an immediate share transfer.